Investigation of Krill Oil in Women with Premenstrual Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

179 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-23

Study Completion Date

2013-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the effects of different dosages and preparations of krill oil in comparison to placebo on symptoms of premenstrual syndrome in healthy, female adults will be assessed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radicle Menstrual Wellness™ CSP: A Trial Evaluating Plant-Based Health and Wellness Products on Menstrual Wellness in Premenopausal Women

NCT07138339

Menstrual Wellness

COMPLETED NA

Efficacy of CL22205 to Improve Menstrual Discomfort and Quality of Life

NCT06760988

Menstrual Discomfort

NOT_YET_RECRUITING NA

Efficacy of a Food Supplement in Relieving Premenstrual Syndrome Symptoms

NCT07013539

Premenstrual Syndrome-PMS

ACTIVE_NOT_RECRUITING NA

An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Hormonal Imbalance

NCT05328609

Hormone Disturbance

COMPLETED NA

Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

NCT06211049

Primary Dysmenorrhea

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a randomized, placebo-controlled, double-blind, parallel group trial, in which the effect of krill oil is investigated in healthy female volunteers showing premenstrual symptoms. The study period covers a time period over 6 menstrual cycles of women under which the first two cycles are recorded to assess baseline conditions followed by a 4-cycle supplementation phase. Volunteers are randomly allocated to the 5 study groups including placebo and 4 different dosages and formulations of krill oil. Over the whole study period, volunteers report daily their symptoms in the validated questionnaire DRSP. Mood state and quality of life are assessed at baseline and after two and 4 cycles of supplementation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premenstrual Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, placebo-controlled, double-blind, parallel group study

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

All participants and study staff were blinded to treatment allocations until the last patient had completed the last visit. The study capsules were identical in shape and color and packed in blisters tailor-made for each intervention group.

Intervention Type OTHER

The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Krill oil

The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).

Intervention Type DIETARY_SUPPLEMENT

Placebo

The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
* Age: 20 - 50 years
* Sex: female
* Premenopausal
* Regular menstrual bleeding
* History of and presence of PMS symptoms of at least 6 months
* Subject is in good physical and mental health as established by medical history, physical examination, electrocardiogram, vital signs, results of biochemistry, haematology

Exclusion Criteria

* BMI: \< 19 kg/m2, ≥ 30 kg/m2
* Heavy smoker \>15 cigarettes / day
* Known pregnancy, breast feeding or intention to become pregnant during the course of the study
* No use of acceptable contraceptive method during the study
* Menstrual cycle lasting less than 24 / longer than 35 days
* Hormone treatment because of premenstrual symptoms
* Diagnosed premenstrual dysphoric disorder (PMDD), a severe form of PMS
* Regular consumption of omega-3 fatty acids (e.g. nutritional supplements) within previous 3 months or during the study course
* Fish consumption of more than 1 serving of fatty fish (e.g herring, mackerel, salmon) per week
* Relevant allergy or known hypersensitivity against compounds of the study preparations
* Unstable medical illness or relevant history or presence of any medical disorder, potentially interfering with this study (e.g. volunteers having experienced any cardiovascular events such as infarction, angina, surgical endocoronary intervention, stroke in the last 6 months or psychiatric disorders / psychoactive medication)
* Clinically relevant abnormal laboratory, ECG, vital signs or physical findings at screening
* Intake of medication potentially interfering with this study
* Known malabsorption / maldigestion
* Drug-, alcohol- and medication abuses
* Known HIV-infection
* Known acute or chronic hepatitis B and C infection
* Blood donation within 2 weeks prior to study start (day 1) or during study
* Participation in any other clinical study within the last 30 days prior to study start or during the study
* Any other condition that, based on Investigator's judgement, makes the subject unfit for inclusion into study
* Anticipating any planned changes in lifestyle for the duration of the study

Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes